Loading...
XSHE
300705
Market cap750mUSD
Jul 09, Last price  
10.17CNY
1D
-0.68%
1Q
-28.63%
IPO
73.42%
Name

Hunan Jiudian Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300705 chart
P/E
10.76
P/S
1.64
EPS
0.95
Div Yield, %
3.08%
Shrs. gr., 5y
8.66%
Rev. gr., 5y
26.04%
Revenues
3.11b
+6.15%
241,413,229266,489,389290,492,436376,400,198534,515,071801,375,318924,061,196978,159,1311,627,664,9422,326,215,8672,692,511,4602,930,677,4973,110,900,254
Net income
473m
-7.72%
36,256,06341,237,04444,642,78954,527,28568,573,38271,985,02455,065,85782,259,772204,245,784269,700,157368,260,795512,377,177472,818,051
CFO
647m
-13.31%
30,692,79030,107,64432,195,18355,182,57280,419,42268,233,50490,740,744149,994,591190,871,610268,988,603431,185,028746,364,584647,057,566
Dividend
May 26, 20250.31297 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hunan Jiudian Pharmaceutical Co., Ltd. is a Chinese pharmaceutical enterprise that spans the entire value chain from drug discovery and development to manufacturing and commercialization. The company's extensive product line includes medications for treating allergies, infections, and inflammatory conditions, as well as analgesics and gynecological remedies. Their offerings further extend to products for digestive health, both Western chemical drugs and traditional Chinese patent medicines, medical equipment, and Active Pharmaceutical Ingredients (APIs). Additionally, Hunan Jiudian provides contract manufacturing services for various pharmaceutical formulations, such as tablets, capsules, granules, and oral liquid preparations like solutions and syrups. The company is headquartered in Changsha, China.
IPO date
Oct 10, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT